MedTrace Logo

Study of Predictive Factors of Chemoresistance in Ovarian Cancer

NCT02878122 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 13

Last updated 2021-08-17

No results posted yet for this study

Summary

Epithelial ovarian cancer (EOC) has a poor prognosis. EOC management requires debulking surgery and chemotherapy based on taxol and carboplatine. Initial response is often good, but most often a recurrence occurred in the first 18 months. Early recurrence signs chemoresistance and palliative treatment. The study of predictive clinical or biological factors is required to adapt therapeutic and develop new treatments.

Conditions

Interventions

PROCEDURE

Cancer treatment

Chemotherapy and laparoscopic surgery

Sponsors & Collaborators

  • Rennes University Hospital

    lead OTHER

Principal Investigators

  • LAVOUE Vincent, Pr · Rennes University Hospital

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2020-03-31
Completion
2020-03-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02878122 on ClinicalTrials.gov